Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Predictive Oncology ( (POAI) ) has issued an update.
On September 9, 2025, Predictive Oncology‘s Board of Directors approved the issuance of restricted stock units (RSUs) as part of their 2024 Equity Incentive Plan. This decision included granting 124,959 RSUs to CEO Raymond F. Vennare and 97,000 RSUs to Interim CFO Josh Blacher, with the RSUs set to vest on October 31, 2025, contingent on continued service.
The most recent analyst rating on (POAI) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Predictive Oncology stock, see the POAI Stock Forecast page.
Spark’s Take on POAI Stock
According to Spark, TipRanks’ AI Analyst, POAI is a Underperform.
The overall stock score is heavily impacted by significant financial challenges, including declining revenues and negative profit margins. The technical analysis indicates a bearish trend, and the valuation reflects ongoing losses with no dividend yield. Additionally, the risk of delisting due to Nasdaq non-compliance further pressures the stock’s outlook.
To see Spark’s full report on POAI stock, click here.
More about Predictive Oncology
Predictive Oncology Inc. operates in the biotechnology industry, focusing on developing and utilizing predictive models and data analytics to enhance cancer treatment outcomes.
Average Trading Volume: 170,025
Technical Sentiment Signal: Sell
Current Market Cap: $10.35M
For a thorough assessment of POAI stock, go to TipRanks’ Stock Analysis page.